Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GHIT Fund to Bankroll 790 Million Yen for Filariasis, Onchocerciasis
November 14, 2022
- Kyowa Kirin Files Romiplate for Aplastic Anemia in Japan
November 14, 2022
- Aculys Pharma Kicks Off Japan PIII of Diazepam Nasal Spray
November 11, 2022
- Otsuka, Takara Bio to End Collaboration for Gene Therapy TBI-1301
November 11, 2022
- Aculys Pharma Launches Japan PIII for Narcolepsy Drug Candidate
November 11, 2022
- KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023
November 11, 2022
- Opdivo Nabs Japan Drug Sales Throne for 10th Month: Encise
November 11, 2022
- Japan Ethical Drug Sales Up 4.7% in September: Crecon
November 11, 2022
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
- Parexel Sees Japan as Key Market, Envisions FSP as Growth Pillar
November 7, 2022
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Nichi-Iko to Discontinue Sales of 95 Generics Mainly on Quality Issues
November 4, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…